• Steve Joys, Nidhi B Panda, Chirag K Ahuja, Ankur Luthra, Manjul Tripathi, Shalvi Mahajan, Narender Kaloria, Chirag Jain, Nidhi Singh, Sabina Regmi, Kiran Jangra, Rajeev Chauhan, Shiv L Soni, and Hemant Bhagat.
• Departments of Anaesthesia and Intensive Care.
• J Neurosurg Anesthesiol. 2023 Jul 1; 35 (3): 327332327-332.

BackgroundStudies have evaluated the effects of volatile and intravenous anesthetic agents on the cerebral vasculature with inconsistent results. We used digital subtraction angiography to compare the effects of propofol and sevoflurane on the luminal diameter of cerebral vessels and on cerebral transit time in patients with aneurysmal subarachnoid hemorrhage (aSAH).MethodsThis prospective preliminary study included adult patients with good-grade aSAH scheduled for endovascular coil embolization; patients were randomized to receive propofol or sevoflurane anesthesia during endovascular coiling. The primary outcome was the luminal diameter of 7 cerebral vessel segments measured on the diseased and nondiseased sides of the brain at 3 time points: awake, postinduction of anesthesia, and postcoiling. Cerebral transit time was also measured as a surrogate for cerebral blood flow.ResultsEighteen patients were included in the analysis (9 per group). Baseline and intraoperative parameters were similar between the groups. Propofol increased the diameter of 1 vessel segment at postinduction and postcoiling on the diseased side and in 1 segment at postcoiling on the nondiseased side of the brain ( P <0.05). Sevoflurane increased vessel diameter in 3 segments at postinduction and in 2 segments at postcoiling on the diseased side, and in 4 segments at postcoiling on the nondiseased side ( P <0.05). Cerebral transit time did not change compared with baseline awake state in either group and was not different between the groups.ConclusionsSevoflurane has cerebral vasodilating properties compared with propofol in patients with good-grade aSAH. However, sevoflurane affects cerebral transit time comparably to propofol.Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

30 keywords...

hide…